Stoke Therapeutics, Inc. 10-Q — AI Bull & Bear Analysis

The Q1 2026 filing paints a picture of a company in a race against time. Stoke has successfully stockpiled capital to reach its primary clinical catalyst, but the cost of maintaining that infrastructure is high. The shift in revenue from $158.6 million to $6.2 million reflects the transition from recognizing upfront partnership fees to the steady-state costs of late-stage development. The core tension for investors is whether the projected 2028 runway is realistic given the accelerating R&D and SG&A spend. Ultimately, Stoke is a high-beta play on the SCN1A target. The ability to maintain the current cash position while executing the EMPEROR trial is the immediate operational goal, but the long-term thesis depends entirely on the mid-2027 data. If successful, the Biogen partnership and the $411 million cushion provide a professional launchpad; if unsuccessful, the company lacks a diversified revenue stream to pivot effectively.